NasdaqGS:ONCBiotechs
BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma
BeOne Medicines' BCL-2 inhibitor sonrotoclax (BEQALZI) has received accelerated FDA approval for relapsed or refractory mantle cell lymphoma.
The decision marks a key regulatory milestone in hematology oncology for patients whose disease persists or returns after prior treatment.
Sonrotoclax is also under review in additional regions and indications across hematologic malignancies.
BeOne Medicines, listed as NasdaqGS:ONC, focuses on targeted therapies in hematology oncology, an area where...